AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

NASDAQ:CRBPCorbus Pharmaceuticals Stock Price, Forecast & News

$6.99
-0.06 (-0.85 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.90
Now: $6.99
$7.55
50-Day Range
$5.63
MA: $6.68
$8.06
52-Week Range
$3.29
Now: $6.99
$8.66
Volume1.97 million shs
Average Volume1.03 million shs
Market Capitalization$506.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Read More
Corbus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.23 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.14 million
Book Value$0.10 per share

Profitability

Net Income$-71,450,000.00
Net Margins-207.87%

Miscellaneous

Employees141
Market Cap$506.71 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

How has Corbus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRBP shares have increased by 69.7% and is now trading at $6.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Corbus Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corbus Pharmaceuticals.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Corbus Pharmaceuticals.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.03. The biopharmaceutical company earned $1.76 million during the quarter, compared to analysts' expectations of $1.64 million. Corbus Pharmaceuticals had a negative net margin of 207.87% and a negative return on equity of 282.91%. View Corbus Pharmaceuticals' earnings history.

What price target have analysts set for CRBP?

5 brokerages have issued 1-year price targets for Corbus Pharmaceuticals' stock. Their forecasts range from $12.00 to $112.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $39.80 in the next twelve months. This suggests a possible upside of 469.4% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals.

Has Corbus Pharmaceuticals been receiving favorable news coverage?

News articles about CRBP stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a coverage optimism score of -3.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutCorbus Pharmaceuticals.

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen, CEO & Director (Age 45, Pay $810.55k)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 62, Pay $520k)
  • Dr. Barbara White, Head of Research & Chief Medical Officer (Age 70, Pay $570.7k)
  • Dr. Robert Paul Discordia Ph.D., Chief Operating Officer (Age 56)
  • Ted Jenkins, Sr. Director of Investor Relations & Communications

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.96%), ETF Managers Group LLC (4.92%), Pinnacle Associates Ltd. (1.69%), State Street Corp (1.60%), Geode Capital Management LLC (1.37%) and Morgan Stanley (1.07%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View institutional ownership trends for Corbus Pharmaceuticals.

Which major investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, AdvisorShares Investments LLC, UBS Group AG, Raymond James & Associates, Morgan Stanley, Morgan Stanley, AE Wealth Management LLC, and Virtus ETF Advisers LLC. View insider buying and selling activity for Corbus Pharmaceuticals.

Which major investors are buying Corbus Pharmaceuticals stock?

CRBP stock was bought by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Carmignac Gestion, DAFNA Capital Management LLC, BlackRock Inc., Geode Capital Management LLC, General American Investors Co. Inc., Alpine Global Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran, and Yuval Cohen. View insider buying and selling activity for Corbus Pharmaceuticals.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $6.99.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $506.71 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.